Neo Achieves Market Cap of 736.27 Million
NEO Stock | USD 17.73 0.17 0.95% |
About 56% of NeoGenomics' investor base is looking to short. The analysis of overall sentiment of trading NeoGenomics stock suggests that many investors are alarmed at this time. NeoGenomics' investing sentiment overview a quick insight into current market opportunities from investing in NeoGenomics. Many technical investors use NeoGenomics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
NeoGenomics |
Neo traded down 0.1 percent against the U.S. dollar during the 24 hour period ending at 800 AM E.T. on January 25th. One Neo coin can currently be bought for 10.44 or 0.00026195 BTC on popular cryptocurrency exchanges. Over the last seven days, Neo has traded down 12.4 percent against the U.S. dollar. Neo has a
Read at thelincolnianonline.com
NeoGenomics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards NeoGenomics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
NeoGenomics Fundamental Analysis
We analyze NeoGenomics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeoGenomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeoGenomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
NeoGenomics is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
NeoGenomics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NeoGenomics stock to make a market-neutral strategy. Peer analysis of NeoGenomics could also be used in its relative valuation, which is a method of valuing NeoGenomics by comparing valuation metrics with similar companies.
Peers
NeoGenomics Related Equities
BDSX | Biodesix | 3.88 | ||||
TWST | Twist Bioscience | 0.23 | ||||
NTRA | Natera | 0.06 | ||||
MTD | Mettler Toledo | 0 | ||||
MYGN | Myriad Genetics | 0.07 | ||||
GH | Guardant Health | 0.52 | ||||
IQV | IQVIA Holdings | 0.65 | ||||
ICLR | ICON PLC | 0.65 | ||||
CSTL | Castle Biosciences | 0.86 | ||||
QGEN | Qiagen NV | 1.22 | ||||
ACRS | Aclaris Therapeutics | 1.53 | ||||
SHC | Sotera Health | 1.87 | ||||
CRL | Charles River | 1.96 | ||||
NEOG | Neogen | 2.72 | ||||
CDNA | Caredx | 2.72 |
Check out NeoGenomics Hype Analysis, NeoGenomics Correlation and NeoGenomics Performance. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.306 | Earnings Share (0.61) | Revenue Per Share 5.098 | Quarterly Revenue Growth 0.104 | Return On Assets (0.03) |
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.